EMA CMC Review Process — The CHMP Assessment Report and What CMC Deficiency Letters Look Like

The EMA CHMP centralized procedure has a 210-day review clock, but it has never taken 210 days for an applicant to discover what a Major Objection on quality looks like.

A Major Objection is CHMP’s formal statement that, as currently documented, the medicinal product does not meet the required quality standards — and a single unresolved Major Objection at Day 150 stops the entire procedure. The FDA equivalent is a Complete Response Letter, except the CHMP Major Objection arrives in a detailed assessment report at Day 120, the applicant has roughly three months to respond, and that response must address every listed issue in a numbered consolidated document the Rapporteur will re-assess before Day 180. US-centric companies filing their first MAA learn what a quality Major Objection means when they receive the Day 120 assessment report, not from regulatory affairs training.

The CHMP 210-Day Assessment Timeline — Day 70 Preliminary Assessment, Day 120 Major Objection Classification, and the Clock Stop That Determines Your European Approval Timeline

Regulation EC 726/2004 establishes the centralized procedure’s active review clock, and the milestones inside that clock are where an MAA CMC package either survives or generates a formal deficiency. Day 1 validates the MAA; Day 70 circulates the Rapporteur and Co-Rapporteur’s preliminary assessment reports to the full CHMP for peer review, giving the applicant an early signal of quality concerns before the formal list is adopted; Day 120 is where CHMP adopts the full assessment report along with the List of Outstanding Issues, and every issue on that list is classified as a Major Objection, a Minor Point, or an Other Concern. A Major Objection is specifically an issue that, left unresolved, would produce a negative opinion, because the product as documented does not meet the required quality standard; a Minor Point should be addressed but isn’t itself grounds for a negative opinion; an Other Concern is advisory. The clock stops at Day 120 while the applicant prepares its response, typically running three months and capped at six before the procedure lapses entirely. For quality specifically, the common Major Objection triggers are an unresolved genotoxic impurity specification gap under ICH M7, drug substance specification limits not aligned with Ph.Eur. general chapters, a manufacturing process description missing identified CPPs or proven acceptable ranges, or stability data insufficient to support the proposed shelf life. If a Day 120 genotoxic impurity Major Objection isn’t resolved with a complete ICH M7 risk assessment and a proposed control strategy, the Rapporteur retains that objection at the Day 150 re-assessment, and CHMP either adopts a Negative Opinion outright or extends the procedure to Day 180 for an oral explanation, neither outcome being one an applicant wants to be discovering as a live possibility for the first time at Day 120.

Ph.Eur. Chromatographic Specificity, EMA Genotoxic Impurity Standards, and the Pharmaceutical Development DoE Requirements That Generate Day 120 CMC Major Objections

The EMA Guideline on the Chemistry of New Active Substances supplements ICH’s drug substance framework with EMA-specific characterization and impurity specification expectations, and one of the most concrete, checkable standards inside that framework is Ph.Eur. 2.2.46’s chromatographic resolution criterion. The resolution factor Rs is calculated as 2(tR2−tR1) divided by the sum of the peak widths at half-height of two adjacent peaks, and Ph.Eur. 2.2.46 requires Rs of at least 2.0 between the principal drug substance peak and any adjacent known impurity peak. An HPLC impurity method showing Rs of 1.8 between the principal peak and the nearest-eluting degradation product falls short of that threshold, and the EMA chemistry reviewer will raise an objection on method specificity, requiring either adjusted chromatographic conditions that actually achieve Rs ≥2.0 or a method validation supplement with peak purity data and spiking experiments demonstrating that the lower resolution still supports adequate quantification at the specification limit. Separately, the EMA Guideline on Pharmaceutical Development expects the 3.2.P.2 section to include actual Design of Experiments data establishing proven acceptable ranges for every identified critical process parameter, not simply a list of CPPs asserted without the underlying justification; a granulation step that names its CPPs but doesn’t provide the DoE dataset behind the proven acceptable ranges is exactly the gap that generates a Major Objection requesting that dataset directly. Both patterns share the same underlying failure mode: a Module 3 built to a standard that documents the conclusion without the EMA-specific evidentiary depth behind it.

Day 120 Consolidated Response Format and the Residual Major Objection Risk — Numbered Issue Addressing, Data Submission Requirements, and the Day 180 Oral Explanation

The Day 120 consolidated response has a specific structural requirement that’s easy to underestimate coming from FDA response conventions: every issue on the List of Outstanding Issues has to be addressed individually, numbered to match the assessment report’s own numbering, with the CHMP question reproduced verbatim, a substantive response running at least a paragraph and typically two to three, and the specific revised or new data referenced by document title and CTD section. Revised Module 3 sections need to be submitted in both tracked-changes and clean versions, and the Quality Overall Summary in Module 2.3 needs updating to reflect every Module 3 change made in response. The single most common route to a Day 180 Residual Major Objection is a response that addresses the CHMP question correctly in principle, agreeing with the concern and describing the intended resolution, but doesn’t actually include the supporting analytical data with the Day 120 submission itself. The Rapporteur’s re-assessment specifically checks whether the promised data arrived, not just whether the applicant’s reasoning was sound, and a commitment to provide data at a later date doesn’t resolve the objection the way the data itself would. A Residual Major Objection surviving into Day 150 forces the procedure toward a Day 180 oral explanation, where the applicant now has to defend a scientific position in real time rather than in a written response prepared with full document review, a materially harder position than simply submitting the complete dataset at Day 120 in the first place.

The XGene EMA MAA CMC Assessment Architecture — Day 70 Readiness, MO Classification, D120 Response Format, Residual Risk, and the Complete CHMP Assessment Navigation Strategy

The XGene EMA MAA CMC Assessment Architecture is a structured CHMP assessment navigation strategy built around the recognition that MAA CMC packages fail not from deficient underlying data but from a submission structured for FDA review conventions rather than CHMP assessment conventions.

1. Day 70 Preliminary Assessment Readiness — Conduct a gap analysis of the MAA CMC package against the EMA Chemistry and Pharmaceutical Development guidelines before submission, using publicly available CHMP assessment reports in the same drug class to anticipate likely preliminary concerns. 2. Day 120 Major Objection Classification Matrix — Map known gap categories against likely classification: ICH M7 non-compliance as a Major Objection, Ph.Eur. specificity below Rs 2.0 as a Minor Point or Major Objection depending on method criticality, and missing DoE data for CPPs as a Major Objection. 3. Day 120 Consolidated Response Format Preparation — Build the numbered issue-by-issue response structure, tracked-changes and clean Module 3 revisions, and updated QOS as a template ready to populate the moment the List of Outstanding Issues is adopted. 4. Residual Major Objection Risk Assessment — Identify which anticipated Day 120 issues carry a realistic risk of becoming Residual Major Objections given the data generation timeline required, and prioritize those data packages first. 5. Day 180 Oral Explanation Preparation — Where a Residual Major Objection risk is identified early, prepare the scientific rationale and anticipate the Rapporteur’s likely follow-up questions well before Day 150.

The output is the complete EMA CMC regulatory strategy that carries an MAA from submission to CHMP Positive Opinion without discovering the CHMP-specific deficiency classification and response format requirements for the first time inside a Day 120 assessment report.

Regulation EC 726/2004 establishes the 210-day centralized procedure timeline, the Major Objection/Minor Point/Other Concern classification, the clock stop mechanism, and the consequences of unresolved Major Objections this article’s analysis is built around. The EMA Guideline on the Chemistry of New Active Substances (EMA/454576/2016) establishes the EMA-specific drug substance characterization and impurity specification requirements CHMP Rapporteurs apply when identifying Day 120 quality Major Objections, while the EMA Guideline on Pharmaceutical Development (EMA/CHMP/167235/2013) establishes the DoE and proven acceptable range requirements behind pharmaceutical development objections. Ph.Eur. 2.2.46 establishes the Rs ≥2.0 chromatographic resolution specificity standard that FDA-centric method validation packages typically don’t address by default.

For your EMA MAA CMC package, can you confirm today that your drug substance impurity specification in 3.2.S.4.1 includes an ICH M7-compliant assessment for every structural alert identified in the synthesis, with either a specification limit at the TTC-calculated level or a documented in-process control strategy, and that your HPLC impurity method validation data demonstrates Rs ≥2.0 between the principal peak and all known adjacent impurity peaks per Ph.Eur. 2.2.46?